Int Arch Otorhinolaryngol 2016; 20(04): 382-389
DOI: 10.1055/s-0036-1583168
Systematic Review
Thieme Publicações Ltda Rio de Janeiro, Brazil

Clinical Value of High Mobility Group Box 1 and the Receptor for Advanced Glycation End-products in Head and Neck Cancer: A Systematic Review

Austin Nguyen
1   Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, United States
,
Sheila Bhavsar
1   Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, United States
,
Erinn Riley
1   Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, United States
,
Gabriel Caponetti
2   Department of Pathology, Creighton University School of Medicine, Omaha, Nebraska, United States
,
Devendra Agrawal
1   Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, United States
› Author Affiliations
Further Information

Publication History

20 January 2016

28 February 2016

Publication Date:
19 April 2016 (online)

Abstract

Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers.

Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas.

Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity.

Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.

 
  • References

  • 1 Czura CJ, Wang H, Tracey KJ. Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001; 7 (4) 315-321
  • 2 Cheng BQ, Jia CQ, Liu CT , et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008; 40 (6) 446-452
  • 3 Lee H, Song M, Shin N , et al. Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS ONE 2012; 7 (4) e34318
  • 4 Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 1973; 38 (1) 14-19
  • 5 Pallier C, Scaffidi P, Chopineau-Proust S , et al. Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol Biol Cell 2003; 14 (8) 3414-3426
  • 6 Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5 (4) 331-342
  • 7 Zhang Z, Wang M, Zhou L , et al. Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res 2015; 34 (1) 51-60
  • 8 Evans A, Lennard TW, Davies BR. High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing?. J Surg Oncol 2004; 88 (2) 86-99
  • 9 Palumbo R, Sampaolesi M, De Marchis F , et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004; 164 (3) 441-449
  • 10 Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004; 255 (3) 320-331
  • 11 Hori O, Brett J, Slattery T , et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270 (43) 25752-25761
  • 12 Nguyen AH, Berim IG, Agrawal DK. Chronic inflammation and cancer: emerging roles of triggering receptors expressed on myeloid cells. Expert Rev Clin Immunol 2015; 11 (7) 849-857
  • 13 Chuah YK, Basir R, Talib H, Tie TH, Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflamm 2013; 2013: 403460
  • 14 Schlueter C, Weber H, Meyer B , et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005; 166 (4) 1259-1263
  • 15 Srinivasan M, Banerjee S, Palmer A , et al. HMGB1 in hormone-related cancer: a potential therapeutic target. Horm Cancer 2014; 5 (3) 127-139
  • 16 Diener KR, Al-Dasooqi N, Lousberg EL, Hayball JD. The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer. Immunol Cell Biol 2013; 91 (7) 443-450
  • 17 Sasahira T, Sasaki T, Kuniyasu H. Interleukin-15 and transforming growth factor alpha are associated with depletion of tumor-associated macrophages in colon cancer. J Exp Clin Cancer Res 2005; 24 (1) 69-74
  • 18 Luo Y, Chihara Y, Fujimoto K , et al. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer 2013; 49 (3) 741-751
  • 19 Kang R, Tang D, Schapiro NE , et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010; 17 (4) 666-676
  • 20 Taguchi A, Blood DC, del Toro G , et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405 (6784) 354-360
  • 21 Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008; 20 (5) 518-523
  • 22 Ellerman JE, Brown CK, de Vera M , et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007; 13 (10) 2836-2848
  • 23 Kang R, Zhang Q, Zeh III HJ, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both?. Clin Cancer Res 2013; 19 (15) 4046-4057
  • 24 Tang D, Kang R, Zeh III HJ, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799 (1–2) 131-140
  • 25 Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 2003; 10 (6) 1863-1868
  • 26 Tarbé N, Evtimova V, Burtscher H, Jarsch M, Alves F, Weidle UH. Transcriptional profiling of cell lines derived from an orthotopic pancreatic tumor model reveals metastasis-associated genes. Anticancer Res 2001; 21 (5) 3221-3228
  • 27 Maeda S, Hikiba Y, Shibata W , et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 2007; 360 (2) 394-400
  • 28 Leman ES, Madigan MC, Brünagel G, Takaha N, Coffey DS, Getzenberg RH. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer. J Cell Biochem 2003; 88 (3) 599-608
  • 29 Dolde CE, Mukherjee M, Cho C, Resar LM. HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat 2002; 71 (3) 181-191
  • 30 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65 (1) 5-29
  • 31 Sasahira T, Kirita T, Bhawal UK , et al. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 2007; 450 (3) 287-295
  • 32 Landesberg R, Woo V, Huang L , et al. The expression of the receptor for glycation endproducts (RAGE) in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105 (5) 617-624
  • 33 Tsuji A, Wakisaka N, Kondo S, Murono S, Furukawa M, Yoshizaki T. Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma. Clin Cancer Res 2008; 14 (17) 5368-5375
  • 34 Su S, Chien M, Lin C, Chen M, Yang S. RAGE gene polymorphism and environmental factor in the risk of oral cancer. J Dent Res 2015; 94 (3) 403-411
  • 35 Sasahira T, Kirita T, Oue N , et al. High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 2008; 99 (9) 1806-1812
  • 36 Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008; 216 (2) 167-175
  • 37 Liu Y, Xie C, Zhang X , et al. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 2010; 46 (16) 3007-3015
  • 38 Wild CA, Brandau S, Lotfi R , et al. HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 2012; 48 (5) 409-416
  • 39 Qiu G, Li Y, Liu Z, Wang M, Ge J, Bai X. Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma. Med Oncol 2014; 31 (12) 316
  • 40 Hanakawa H, Orita Y, Sato Y , et al. Does HMGB1 predict occult neck lymph node metastasis in early tongue carcinoma? A case-control study of 26 patients. J Laryngol Otol 2014; 128 (10) 926-931
  • 41 Supic G, Kozomara R, Zeljic K , et al. HMGB1 genetic polymorphisms in oral squamous cell carcinoma and oral lichen planus patients. Oral Dis 2015; 21 (4) 536-543